Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Abu-Rustum, Nadeem; Yashar, Catheryn; Arend, Rebecca; Barber, Emma; Bradley, Kristin; Brooks, Rebecca; M Campos, Susana; Chino, Junzo; Sook Chon, Hye; Chu, Christina; Ann Crispens, Marta; Damast, Shari; M Fisher, Christine; Frederick, Peter; K Gaffney, David; Giuntoli, Robert; Han, Ernest; Holmes, Jordan; E Howitt, Brooke; Lea, Jayanthi; Mariani, Andrea; Mutch, David; Nagel, Christa; Nekhlyudov, Larissa; Podoll, Mirna; Salani, Ritu; Schorge, John; Siedel, Jean; Sisodia, Rachel; Soliman, Pamela; Ueda, Stefanie; Urban, Renata; L Wethington, Stephanie; Wyse, Emily; Zanotti, Kristine; R McMillian, Nicole; Aggarwal, Shaili

doi:10.6004/jnccn.2023.0006

Public

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.

Published in Journal of the National Comprehensive Cancer Network : JNCCN • Feb 1, 2023

NobleIDark:/48914/w1/20260526/8D9B3703Record on NobleID

Authors:

Nadeem Abu-Rustum

,

Catheryn Yashar

,

Rebecca Arend

Abstract

Adenocarcinoma of the endometrium (also known as endometrial cancer, or more broadly as uterine cancer or carcinoma of the uterine corpus) is the most common malignancy of the female genital tract in the United States. It is estimated that 65,950 new uterine cancer cases will have occurred in 2022, ...

Discussions